NCT05936346 Evaluation of Safety and Tolerability of Salvia Haenkei Extract As a Dietary Supplement Ingredient
| NCT ID | NCT05936346 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IBSA Farmaceutici Italia Srl |
| Condition | Aging |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-07-17 |
| Primary Completion | 2025-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2023-07-17 with a primary completion date of 2025-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Evalution of the safety and tolerability of the oral administration of Salvia haenkei in a healthy population.
Eligibility Criteria
Inclusion Criteria: * Informed consent as documented by signature * Male or female * Age 55-65 years, inclusive * In good general health as evidenced by medical history and current health status * Willingness to maintain dietary and sports habits as of baseline * Willingness and ability to comply with the requirements of the study Exclusion Criteria: * Body Mass Index \< 18.5 or ≥ 30 * Difficulty in swallowing (dysphagia) * Known allergy or sensitivity to any ingredient of the study intervention * Any medical condition or clinically significant abnormalities in laboratory values (hematology, blood chemistry, urinalysis) at screening which in the judgment of the Investigator makes the subject unsuitable for the study * Planned or anticipated major surgical procedure during the subject's participation in this study * Inability or contraindications to undergo the study intervention * Inability to follow the procedures of the study (e.g. due to language problems, psychological disorders, dementia, etc.) * Use of any new vitamins, herbal or dietary supplements, functional foods and sports drink, of any kind, liable or presented as liable to enhance physical performances within one month prior to the start and during the study
Contact & Investigator
Roberta Noseda, MD, PhD
PRINCIPAL INVESTIGATOR
Istituto di Scienze Farmacologiche della Svizzera Italiana, Lugano (Switzerland)
Frequently Asked Questions
Who can join the NCT05936346 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, up to 65 Years, studying Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05936346 currently recruiting?
Yes, NCT05936346 is actively recruiting participants. Contact the research team at Tatiana.Terrot@eoc.ch for enrollment information.
Where is the NCT05936346 trial being conducted?
This trial is being conducted at Lugano, Switzerland.
Who is sponsoring the NCT05936346 clinical trial?
NCT05936346 is sponsored by IBSA Farmaceutici Italia Srl. The principal investigator is Roberta Noseda, MD, PhD at Istituto di Scienze Farmacologiche della Svizzera Italiana, Lugano (Switzerland). The trial plans to enroll 50 participants.